GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

GSK PLC closed 23.31% below its 52-week high of £18.24, which the company reached on May 16th.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...